Wuxi Biologics
TOPIC
 / company

Wuxi Biologics

Wuxi Biologics
Wuxi Biologics
Wuxi Biologics is a pharmaceutical research and services company based in Wuxi, Jiangsu province. It counts 16 of the world's top 20 drug makers as customers and 28 of China's 50 largest medicine producers. The company supplied ingredients for AstraZeneca's Covid-19 vaccine. It is one of six businesses founded by its chairman Ge Li, along with Wuxi Apptec.
Chairman / President
Li Ge
CEO / Managing Director
Chen Zhisheng
CFO / Finance Director
Tu Ming
Industry
Biopharmaceutical
Website
wuxibiologics.com.cn
Headquarters address
No. 108 Mashan Meiliang Road, Binhu Distroct, Wuxi City, Jiangsu Province, China
Stock Code
SEHK:2269
Year founded
2010
LATEST China Science NEWS

As Trump taps coal to power AI, China moves on to clothe the world with it

videocam
China is turning the fossil energy resource into nylon, spurring on its economy with the manufacture of sportswear and other popular fashion items. Photo: Xinhua

China builds world-first crab-walking electric ICBM mobile launcher prototype

videocam
21
The prototype modular electric-drive heavy-duty truck. Photo: Tsinghua University

China to power up world’s largest ‘super-cold air battery’ in the Gobi Desert

videocam
8
In the Gobi Desert outside Golmud, Qinghai, a facility is using compressed air to store energy. Photo: Handout

Chinese 6G smart surface could allow stealth jets to use radar as a power source

videocam
14
The development could given China an edge in the development of 6G technology. Photo: Shutterstock

Chinese nuclear experts believe Japan could build nukes in less than 3 years

videocam
152
Some Chinese nuclear experts estimate that Japan has the capacity to develop nuclear weapons in less than three years. Photo: Shutterstock
MORE China Science NEWS
US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Science

Why US lawmakers killed a proposal targeting science efforts with China

videocam
11
China manufacturing

China’s biotech firms may see ‘major breakthroughs’ within a decade. Here’s why

videocam
Shanghai

China bets on bio-manufacturing as new growth engine, bid for tech self-reliance

The pilot-scale platforms are aimed at helping innovators overcome hurdles in R&D and manufacturing before achieving commercial production.

Biotech manufacturing has been identified as one of the key economic growth drivers in China’s 15th five-year plan. Photo: Shutterstock
Hong Kong stock market

Ignore China’s innovation boom ‘at your own peril’, General Atlantic CEO warns

Easing of US-China tensions and strong Hong Kong equity market present new opportunities, William Ford says at the Family Business Summit.

Hong Kong stock market

Hong Kong stocks post longest decline in 9 months on renewed US-China tensions

Markets react to Trump’s threat to impose a 100 per cent tariff on all Chinese imports and restrict critical software exports from November.

Advertisement
Advertisement
Advertisement
Biomedicine: Geopolitics

Trump’s tariffs on imported drugs ‘not a big concern’ for China’s pharma firms

Chinese drug makers have ‘minimal sales exposure to the US’, Jefferies analysts say.

The Trump administration’s new 100 per cent tariff on any branded or patented pharmaceutical product takes effect on October 1. Photo: Shutterstock
Hong Kong stock market

Hong Kong stocks cap weekly decline on valuation, tariff jitters

‘Gravity has reasserted itself’ and the global US$15 trillion rebound this year ‘now feels stretched’, investor says.

Hong Kong stock market

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

Biomedicine: Companies

Chinese biotech firm MGI’s DNA sequencers gaining in the market, BGI CEO says

MGI’s latest product, the DNBSEQ-T7+, can sequence 144 human genomes a day, or one every 10 minutes.

MGI Tech’s DNA sequencers offer the best “comprehensive value” in terms of time, quality and cost, according to BGI Group CEO Yin Ye. Photo: Shutterstock
Hong Kong stock market

Hong Kong stocks slip from 4-year high amid fears of US sanctions on drug makers

The Trump administration has been discussing severe restrictions on medicines from China, according to The New York Times.

Hong Kong stocks fell on Thursday. Photo: EPA
Hong Kong stock market

Alibaba surge leads Hong Kong stocks to biggest gain in 2 weeks

Hong Kong stocks are undervalued, and a ‘liquidity friendly environment’ is set to propel them higher, analyst says.

Hong Kong stock market

Hong Kong stocks rebound on US-China trade talk optimism

Hang Seng Index recovers from an intraday loss of as much as 0.9 per cent, snapping a four-day losing streak.

Hong Kong stock market

Hong Kong stocks sustain 3-year-high level on trade optimism

A US deal with Japan and scheduled talks with China reduce concerns about damage to the global economy from trade conflicts.

A crane lifts cargo from a container ship at the Port of Oakland in Oakland, California on July 14, 2025. Photo: EPA
Hong Kong stock market

Hong Kong stocks cap weekly gain on earnings optimism

Wuxi AppTec jumps after it says its first-half profit likely more than doubled from a year earlier.

Exchange Square in Central. Photo: Reuters
Hong Kong stock market

Hong Kong stocks gyrate amid Iran conflict after US strike, Hormuz threat

Oil futures surge after US President Donald Trump says attacks ‘obliterated’ targets and Iran threatens to close key oil shipping route.

Hong Kong stock market

Hong Kong stocks rise on China policy hopes after soft economic data

China’s industrial output and fixed-asset investment fell short in May, and the downturn in the property market deepened.

Advertisement
Advertisement
Advertisement
Hong Kong stock market

Hong Kong stocks erase gains amid ongoing US-China trade talks

Investors appear to look more cautiously at ongoing US-China trade talks in London.

Exchange Square in Central. Photo: Sam Tsang
Hong Kong stock market

Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade

Hang Seng Index approached a two-month high on bets global trade relations and market sentiment will improve.

videocam
Hong Kong stock market

Hong Kong stocks gain on earnings boost as Meituan beats market consensus

Gains limited by losses in leading carmakers amid lingering concerns about a prolonged price war.

videocam
Biomedicine: Companies

Big Chinese pharma can beat Trump’s policies with cost efficiencies: analysts

Trump seeks to slash domestic drug prices, bring back pharmaceutical manufacturing to the US and slap tariffs on imports.

videocam
A humanoid robot is shown delivering drugs at a mock pharmacy in Beijing in April 2025. Photo: EPA-EFE
China Future Tech briefing

Biomedicine | China’s biomedical sector braces for headwinds

The coast isn’t entirely clear for the world’s second-largest biomedical sector, which faces possible tariff increases and US import curbs.

***PLUS ONLY PLEASE DO NOT USE***
Biomedicine: Companies

China’s WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation explicitly names WuXi.

Biomedicine: Companies

WuXi AppTec, WuXi Biologics surge on slimmer chances of Biosecure Act’s passage

The bill’s absence from the proposed amendments to the US National Defence Authorisation Act comes as a reprieve for the two biotech firms.

Biomedicine: Policy

Shanghai to back local biopharma firms’ overseas push, regulatory compliance

The initiative aims to generate about US$7 billion from medical product exports by 2027.

videocam
The latest action plan by Shanghai’s municipal government is expected to help local biopharmaceutical firms go global. Photo: Shutterstock
Wuxi AppTec

WuXi AppTec, WuXi Biologics rise in Hong Kong as some operations go up for sale

The gains were made on the back of a report that said the two firms plan to sell certain overseas operations amid heightened US scrutiny.

The reported divestment plans of WuXi AppTec and WuXi Biologics show their efforts to head off the potential impact of the US Biosecure Act. Photo: Shutterstock
US-China relations

Senior US official lauds China cooperation on tech-transfer controls

‘End-use checks’ have improved since the pandemic, but pending congressional legislation is keeping mainland firms in limbo.

videocam
6
US-China relations

‘China week’ at US House puts biotech firms, Hong Kong offices in cross hairs

Most of the scheduled 28 items have bipartisan support and follow efforts to tackle national and economic security threats posed by Beijing.

videocam
19
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement